NCT07830849

Brief Summary

Chronic wounds are skin lesions that fail to heal within the expected timeframe and are frequently associated with underlying conditions such as diabetes, cardiovascular disease, obesity, and other chronic diseases. Their assessment is currently based primarily on clinical observation and standardized wound assessment tools. However, clinical evaluation may be affected by inter- and intra-clinician variability, potentially limiting the objectivity and reproducibility of wound characterization and monitoring. This multicenter, interventional, non-profit pilot study aims to investigate the feasibility of using non-invasive imaging technologies to support the quantitative and objective characterization of chronic wounds. The study will evaluate the use of multimodal imaging, including ultrasound, high-resolution digital imaging, infrared thermography, and laser Doppler imaging, in patients with chronic wounds. The primary hypothesis is that the use of complementary non-invasive imaging technologies may provide objective and reproducible information on wound characteristics and may show good agreement with standardized clinical wound assessment. The study will also explore whether the combination of information obtained through different imaging modalities may improve the characterization and monitoring of chronic wounds compared with clinical assessment alone. Approximately 40 adult patients with chronic wounds, including pressure ulcers and venous ulcers, will be enrolled at participating clinical centers. Eligible participants will undergo repeated clinical assessments and non-invasive imaging examinations during the study period. Wound exudate may also be collected at predefined time points for exploratory analyses. The primary objective is to assess the agreement and reproducibility between imaging-based wound characterization and standard clinical assessment. The study will also evaluate the performance of the individual imaging modalities and their combined use in characterizing relevant wound features. Exploratory objectives include investigating the potential of the collected data to support the development of quantitative and predictive approaches for wound assessment and monitoring. The study will also explore the relationship between imaging-derived parameters and biological information obtained from wound exudate. The study is intended as a pilot investigation to generate preliminary evidence on the feasibility and potential clinical value of multimodal imaging for the objective assessment of chronic wounds. The results may provide a basis for future clinical validation studies and for the development of innovative approaches to support chronic wound management.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 15, 2026

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

September 9, 2026

Completed
12 days until next milestone

First Posted

Study publicly available on registry

September 21, 2026

Completed
3 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 24, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 24, 2026

Completed
Last Updated

September 21, 2026

Status Verified

September 1, 2026

Enrollment Period

5 months

First QC Date

September 9, 2026

Last Update Submit

September 15, 2026

Conditions

Outcome Measures

Primary Outcomes (3)

  • Inter-Rater Agreement of Total BWAT Score Among Clinicians

    Agreement among clinicians in the assessment of chronic wound characteristics will be evaluated using the Bates-Jensen Wound Assessment Tool (BWAT). The total BWAT score, ranging from 13 to 65, will be treated as a continuous variable. Agreement among clinical evaluators will be assessed using the Intraclass Correlation Coefficient (ICC), with 95% confidence intervals, at each predefined assessment time point.

    Days 1, 7, 14, and 21

  • Agreement Between Individual Imaging Technologies and Clinical Assessment of BWAT Items

    Each of the four imaging technologies-ultrasound, high-resolution digital imaging, infrared thermography, and laser Doppler imaging-will be evaluated separately for its ability to characterize individual wound features corresponding to items of the Bates-Jensen Wound Assessment Tool (BWAT). For each imaging technology, the imaging-based assessment of individual BWAT items will be compared with the corresponding clinical assessment. Agreement will be evaluated separately for each BWAT item and at each predefined assessment time point using the Overall Coefficient of Concordance (OCCC). Diagnostic performance will additionally be assessed, as applicable, using sensitivity, specificity, overall accuracy, receiver operating characteristic (ROC) curves and area under the ROC curve (AUC), and confusion matrices.

    Days 1, 7, 14, and 21

  • Agreement Between Individual Imaging Technologies and Clinical Total BWAT Score

    Each of the four imaging technologies-ultrasound, high-resolution digital imaging, infrared thermography, and laser Doppler imaging-will be evaluated separately with respect to the total Bates-Jensen Wound Assessment Tool (BWAT) score obtained by clinical assessment. The total BWAT score ranges from 13 to 65 and will be treated as a continuous variable. For each imaging technology, the total BWAT score derived from the imaging-based assessment will be compared with the total BWAT score obtained by standard clinical assessment. Agreement between imaging-based and clinical assessments will be evaluated using the Intraclass Correlation Coefficient (ICC), with 95% confidence intervals, at each predefined assessment time point. Diagnostic performance measures may additionally be calculated, as applicable, to characterize the ability of each imaging technology to reproduce the clinically assessed total BWAT score.

    Days 1, 7, 14, and 21

Study Arms (1)

Multimodal Non-Invasive Imaging Assessment

EXPERIMENTAL
Diagnostic Test: Quantitative Imaging-Based Chronic Wound Assessment

Interventions

The intervention consists of a multimodal, non-invasive imaging approach for the quantitative assessment of chronic wounds. Participants will undergo wound imaging using complementary imaging modalities, including ultrasound, high-resolution digital imaging, infrared thermography, and laser Doppler imaging. The acquired data will be analyzed to obtain quantitative information on relevant wound characteristics and to support standardized wound assessment. Imaging-based findings will be compared with conventional clinical wound assessment to evaluate their concordance, reproducibility, and potential diagnostic value. Repeated assessments will be performed during the study to explore the potential of the approach for monitoring wound evolution over time.

Multimodal Non-Invasive Imaging Assessment

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients of both sexes aged over 18 years;
  • Patients with a chronic venous or pressure wound. In the case of venous wounds, the diagnosis must be confirmed by Doppler examination. The wound must have been present for at least 6 weeks and show less than 50% reduction in wound area after 30 days of standard treatment;
  • Patients with chronic wounds up to Grade III.

You may not qualify if:

  • Pregnancy or breastfeeding;
  • Patients with signs of systemic infection (MEWS \> 0);
  • Patients with active neoplastic disease, hematological disorders affecting coagulation, or systemic inflammatory autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus);
  • Individuals unable to manage their own interests or provide valid informed consent, even if represented by a legal representative who has provided consent to participation;
  • Ankle-Brachial Index (ABI) \< 0.8;
  • Body Mass Index (BMI) \> 40.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Scuola Superiore Sant'Anna, The BioRobotics Institute

Pontedera, Pisa, 56025, Italy

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 9, 2026

First Posted

September 21, 2026

Study Start

April 15, 2026

Primary Completion

September 24, 2026

Study Completion

September 24, 2026

Last Updated

September 21, 2026

Record last verified: 2026-09

Locations